Akhter S.,Chonbuk National University |
Rahman M.M.,Chonbuk National University |
Lee H.S.,Chonbuk National University |
Kim H.-J.,JINIS Biopharmaceuticals Co. |
Hong S.-T.,Chonbuk National University
Protein and Cell | Year: 2013
Recent advances in hematopoietic stem cells (HSCs) expansion by growth factors including angiopoietin-like proteins (Angptls) have opened up the possibility to use HSCs in regenerative medicine. However, the unavailability of true in vitro HSCs expansion by these growth factors has limited the understanding of the cellular and molecular mechanism of HSCs expansion. Here, we report the functional role of mouse Angptls 1, 2, 3, 4, 6 and 7 and growth factors SCF, TPO, IGF-2 and FGF-1 on purified mouse bone-marrow (BM) Lineage-Sca-1+(Lin-Sca-1+) HSCs. The recombinant retroviral transduced-CHO-S cells that secrete Angptls in serum-free medium were used alone or in combination with growth factors (SCF, TPO, IGF-2 and FGF-1). None of the Angptls stimulated HSC proliferation, enhanced or inhibited HSCs colony formation, but they did support the survival of HSCs. By contrast, any of the six Angptls together with saturating levels of growth factors dramatically stimulated a 3- to 4. 5-fold net expansion of HSCs compared to stimulation with a combination of those growth factors alone. These findings lead to an understanding of the basic function of Angptls on signaling pathways for the survival as well as expansion of HSCs in the bone marrow niche. © 2013 Higher Education Press and Springer-Verlag Berlin Heidelberg. Source
Pandeya D.R.,Chonbuk National University |
Pandeya D.R.,Nepal Army Institute of Health science |
D'Souza R.,Chonbuk National University |
Rahman M.M.,Chonbuk National University |
And 3 more authors.
Biomedical Research | Year: 2012
The mammalian gut has coevolved over millions of years with a vast consortium of microbes, which were physically, intimately and densely associated with our body. From birth, this population is in continuous and intimate contact with intestinal tissues. Recent results indicate that indigenous bacteria play a crucial inductive role in gut development during early postnatal life. These findings have revealed that the mammalian intestine is poised for interaction with its prokaryotic partners, which are essential for its normal development. During their coevolution, the bacterial microbiota has established multiple mechanisms to influence the eukaryotic host, generally in a beneficial fashion, and maintain their stable niche. The prokaryotic genomes of the human microbiota encode a spectrum of metabolic capabilities beyond that of the host genome, making the microbiota an integral component of human physiology. Gaining a fuller understanding of both partners in the normal gutmicrobiota interaction may shed light on how the relationship can go awry and contribute to a spectrum of immune, inflammatory, and metabolic disorders and may reveal mechanisms by which this relationship could be manipulated toward therapeutic ends. This review provides a brief overview of this exciting, emerging field. Source
Chung H.J.,Chonbuk National University |
Hassan M.M.,Chonbuk National University |
Park J.O.,Chonbuk National University |
Park J.O.,University of Louisville |
And 2 more authors.
Brazilian Journal of Medical and Biological Research | Year: 2015
Recent advances have raised hope that transplantation of adherent somatic cells could provide dramatic new therapies forvarious diseases. However, current methods for transplanting adherent somatic cells are not efficient enough for therapeuticapplications. Here, we report the development of a novel method to generate quasi-natural cell blocks for high-efficiencytransplantation of adherent somatic cells. The blocks were created by providing a unique environment in which cultured cellsgenerated their own extracellular matrix. Initially, stromal cells isolated from mice were expanded in vitro in liquid cell culturemedium followed by transferring the cells into a hydrogel shell. After incubation for 1 day with mechanical agitation, theencapsulated cell mass was perforated with a thin needle and then incubated for an additional 6 days to form a quasi-naturalcell block. Allograft transplantation of the cell block into C57BL/6 mice resulted in perfect adaptation of the allograft andcomplete integration into the tissue of the recipient. This method could be widely applied for repairing damaged cells or tissues,stem cell transplantation, ex vivo gene therapy, or plastic surgery. © 2015, Associacao Brasileira de Divulgacao Cientifica. All Rights Reserved. Source
Jinis Biopharmaceuticals Co. | Date: 2011-05-16
This invention provides compositions and methods for producing low cholesterol poultry eggs using hypocholesterolemic compounds, cholesterol lowering supplements, and feeds therefrom. The compositions include industrial by-products obtained during production of pravastatin as effective ingredients for lowering the cholesterol content in eggs. The present invention enables the production of eggs with greatly reduced cholesterol content in an economical way. Therefore, the present invention can be considered the first technique suitable for practical use in the production of low cholesterol eggs using statins.
Chung H.-J.,Chonbuk National University |
Yu J.G.,JINIS Biopharmaceuticals Co. |
Lee I.-A.,JINIS Biopharmaceuticals Co. |
Liu M.-J.,Chonbuk National University |
And 6 more authors.
FEBS Open Bio | Year: 2016
Recent findings on the association of gut microbiota with various diseases, including obesity, prompted us to investigate the possibility of using a certain type of gut bacteria as a safe therapeutic for obesity. Lactobacillus mutants with enhanced capacity in absorption of free fatty acids (FFAs) were isolated to show reduced absorption of FFAs by the administered host, attributing to inhibition of body weight gain and body fat accumulation as well as amelioration of blood profiles. Consequently, high throughput screening of natural FFAs-absorbing intestinal microbes led to the isolation of Lactobacillus reuteri JBD30 l. The administration of Lactobacillus JBD30l lowered the concentration of FFAs in the gut fluid content of small intestine, thus reducing intestinal absorption of FFAs whereas promoting fecal excretion of FFAs. Animal data also confirmed that the efficacy of Lactobacillus JBD30l on body weight similar to that of orlistat, an FDA-approved pharmaceutical for long-term use to treat obesity. In a subsequent random, double-blind, placebo-controlled clinical trial (KCT0000452 at Clinical Research Information Service of Korea), there was a statistically significant difference in the percentage change in body weight between the Lactobacillus JBD301 and the placebo group (P = 0.026) as well as in the BMI (P = 0.036) from the 0-week assessment to the 12-week assessment. Our results show that FFA-absorbing Lactobacillus JBD301 effectively reduces dietary fat absorption, providing an ideal treatment for obesity with inherent safety. © 2015 The Authors. Published by FEBS Press and John Wiley & Sons Ltd. Source